Innate Pharma Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Jonathan Dickinson
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 2.9yrs |
| Board average tenure | 6.2yrs |
Recent management updates
Recent updates
Subdued Growth No Barrier To Innate Pharma S.A. (EPA:IPH) With Shares Advancing 37%
Dec 20
Risks To Shareholder Returns Are Elevated At These Prices For Innate Pharma S.A. (EPA:IPH)
Oct 24Benign Growth For Innate Pharma S.A. (EPA:IPH) Underpins Its Share Price
May 21Innate Pharma S.A. (EPA:IPH) Annual Results: Here's What Analysts Are Forecasting For This Year
Mar 24Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Dec 21Analysts' Revenue Estimates For Innate Pharma S.A. (EPA:IPH) Are Surging Higher
Sep 30Some Innate Pharma S.A. (EPA:IPH) Analysts Just Made A Major Cut To Next Year's Estimates
Sep 16Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Jun 09News Flash: Analysts Just Made A Massive Upgrade To Their Innate Pharma S.A. (EPA:IPH) Forecasts
Mar 30Rainbows and Unicorns: Innate Pharma S.A. (EPA:IPH) Analysts Just Became A Lot More Optimistic
Dec 18Does Innate Pharma (EPA:IPH) Have A Healthy Balance Sheet?
Sep 27Innate Pharma S.A. (EPA:IPH) Analysts Are Reducing Their Forecasts For This Year
Aug 04Industry Analysts Just Made A Dazzling Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts
May 12Industry Analysts Just Made A Captivating Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts
Apr 13Time To Worry? Analysts Just Downgraded Their Innate Pharma S.A. (EPA:IPH) Outlook
Mar 26Is Innate Pharma (EPA:IPH) Weighed On By Its Debt Load?
Nov 11CEO
Jonathan Dickinson (56 yo)
less than a year
Tenure
Mr. Jonathan E. Dickinson served as Executive Vice President and General Manager of Europe at Incyte Corp. since June 2019 until October 2024. He served as General Manager of Europe/International and Senio...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive VP | 9.7yrs | €599.92k | 0.24% € 353.8k | |
| Chairman of the Executive Board & CEO | less than a year | no data | no data | |
| Founder | no data | no data | no data | |
| Founder | 7yrs | no data | 0.26% € 383.0k | |
| Founder | no data | no data | no data | |
| Founder | no data | no data | no data | |
| Founder | no data | no data | no data | |
| Senior VP & CFO | 3.8yrs | no data | 0.014% € 20.7k | |
| Executive VP | less than a year | no data | no data | |
| Executive VP | less than a year | no data | no data | |
| Vice President of Investor Relations & Communication | 2yrs | no data | 0.0039% € 5.8k | |
| Vice President of Compliance & Operations | 6yrs | no data | 0.077% € 113.4k |
2.9yrs
Average Tenure
56yo
Average Age
Experienced Management: IPH's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Strategic Advisory Board Member | 6.2yrs | no data | no data | |
| Member of Supervisory Board | no data | no data | no data | |
| Strategic Advisory Board | less than a year | no data | no data | |
| Independent Member of Supervisory Board | 17.6yrs | €29.00k | 0.090% € 133.1k | |
| Independent Supervisory Board Member | 2.7yrs | €45.00k | 0.0031% € 4.6k | |
| Independent Member of Supervisory Board | 7.1yrs | €29.00k | 0.000060% € 88.5 | |
| Independent Chairwoman of Supervisory Board | 15.6yrs | €42.00k | 0.031% € 45.7k | |
| Independent Vice Chairperson of the Supervisory Board | 4.7yrs | €60.00k | 0.0012% € 1.8k | |
| Chairman of Strategic Advisory Board | 6.2yrs | no data | no data | |
| Independent Member of Supervisory Board | 9.8yrs | €48.00k | 0.00082% € 1.2k | |
| Strategic Advisory Board | less than a year | no data | no data | |
| Strategic Advisory Board Member | 6.2yrs | no data | no data |
6.2yrs
Average Tenure
62.5yo
Average Age
Experienced Board: IPH's board of directors are considered experienced (6.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 08:52 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Innate Pharma S.A. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Olga Smolentseva | Bryan Garnier & Co |
| Yigal Nochomovitz | Citigroup Inc |
| Michael Thomas Cooper | Edison Investment Research |